Arachidonic acid (AA) metabolites derived from both cyclooxygenase (COX) and lipoxygenase (LOX) protein, a dramatic decrease in the bcl-2/bax ratio, and could be suppressed by bcl-2 overexpression. In contrast, p53, which is wild type in W256 cells, did not undergo alterations during apoptosis induction. The results suggest that the LOX pathway plays an important physiological role in regulating apoptosis.
ABSTRACT
Arachidonic acid (AA) metabolites derived from both cyclooxygenase (COX) and lipoxygenase ( 15 (S)-hydroxyeicosatetraenoic acids. The W256 cell apoptosis induced by antisense oligos and LOX inhibitors was followed by a rapid downregulation of bcl-2 protein, a dramatic decrease in the bcl-2/bax ratio, and could be suppressed by bcl-2 overexpression. In contrast, p53, which is wild type in W256 cells, did not undergo alterations during apoptosis induction. The results suggest that the LOX pathway plays an important physiological role in regulating apoptosis.
Apoptosis, or programmed cell death, plays an indispensable role in embryonic development, maturation of the immune system, and maintenance of tissue and organ homeostasis. A wide spectrum of molecular entities including oncogenes, tumor suppressor genes, signal transducers, cell cycle proteins, free radicals, cations, and proteases (1, 2) have been implicated in apoptosis. Arachidonic acid (AA) metabolites derived from both lipoxygenase (LOX) and cyclooxygenase (COX) pathways have been shown to transduce growth-related signals and regulate cell proliferation (3, 4) . However, no information is available as to whether these potent biological metabolites are also involved in the regulation of cell survival. Studies presented here show that the AA LOX system also plays a significant, physiological role in regulating cell survival and apoptosis.
MATERIALS AND METHODS
Cell Culture and Materials. W256 cells, which arose spontaneously in the mammary gland of a pregnant albino rat and recently were shown to be of hematopoietic (i.e., monocytoid) origin (5) , were maintained in minimum essential medium supplemented with antibiotics and 5% fetal calf serum (FCS) as described (6) . All chemicals and inhibitors were purchased from Biomol (Plymouth Meeting, PA). Various eicosanoids were bought from either Cayman Chemicals (Ann Arbor, MI) or Oxford and their specified purities were always >99%. Lipofectin was obtained from Life Technologies (Grand Island, NY).
DNA Fragmentation Assay and Quantitation ofFragmented DNA. Fragmented DNA was extracted using SDS/RNase/ Proteinase K method (7) and 20 gg of DNA was run on a 1.2% agarose gel. To quantitate DNA fragmentation, W256 cells labeled with 3H-thymidine (1 ,uCi/ml, 18 h; 1 Ci = 37 GBq)
were treated as described in Results and Discussion. Subsequently, both fragmented DNA in the supernatants and intact genomic DNA were isolated and ethanol precipitated. The % of the DNA fragmentation was obtained using the formula [% = cpm of fragmented DNA/(cpm of fragmented DNA + cpm of intact genomic DNA)].
Determination of Cell Survival. The number of living W256 cells following treatment with antisense oligonucleotides or inhibitors was determined by counting on a Coulter counter or by the trypan blue dye exclusion assay.
Oligonucleotide Synthesis, Purification, and Characterization. Various oligonucleotides of 15-20 bases were synthesized either in our own lab on a Gene Assembler Plus (Pharmacia LKB) or by Integrated DNA Technology (Coralville, IA). All oligos were purified by size exclusion chromatography and the purity was characterized by PAGE and/or HPLC analysis.
Transfection of Oligonucleotides and Plasmid Expression Vectors into W256 Cells. W256 cells were transfected with various concentrations of oligonucleotides in the presence of 10 Ag/ml Lipofectin (BRL) in serum-free MEM for 4 h, after which the oligonucleotides were washed off and cells were cultured in MEM supplemented with 5% FCS for up to 24 h (day 1). The treatment was repeated every 24 h until day 5. To construct bcl-2 expression vector, the full-length human bcl-2 cDNA [1.9 kb; provided by S. J. Korsmeyer (Washington University, St. Louis)] was cloned into a eukaryotic expression vector that carries the cytomegalovirus promoter and a minicassette conferring neomycin resistance (pCMVbcl-2). The empty vector without the insert (pCMVneo) was used as the control. pCMVneo or pCMVbcl-2 (1 ,ug) purified by PEG precipitation was transfected into W256 cells using Lipofectin (10 ,ug/ml). Selection was initiated 48 h after the transfection with 800 ,ug/ml G418 (Life Technologies). Individual resistant clones were isolated using the limiting dilution method and propagated in serum-containing MEM supplemented with 300 jig/ml G418.
Terminal Deoxynucleotidyltransferase-Mediated UTP End Labeling (TUNEL) of Apoptotic Cells and Confocal Microscopy. Apoptotic W256 cells following treatment with either antisense oligos or inhibitors were detected using the TUNEL method (8) with the ApopTag kit (Oncor). The labeled cells were examined using a confocal microscope (9, 10) .
Immunoblotting. Immunoblotting was performed essentially as described using the enhanced chemiluminescence system (6, 9).
RESULTS AND DISCUSSION
Previous studies showed that W256 cells express platelet-type 12-LOX and biosynthesize 12(5)-and 15(S)-hydroxyeicosatetraenoic acids (HETEs) as their major LOX products (11) (12) (13) .
Abbreviations: AA, arachidonic acid; HETE, hydroxyeicosatetraenoic acid; HPETE, hydroperoxyeicosatetraenoic acid; NDGA, nordihydroguaiaretic acid; BHPP, N-benzyl-N-hydroxy-5-phenylpentanamide; COX, cyclooxygenase; LOX, lipoxygenase; TUNEL, terminal deoxynucleotidyltransferase-mediated UTP end labeling. §To whom reprint requests should be addressed.
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. To explore the role of the W256 LOX(s) in cell growth, W256 cells were transfected with an antisense oligonucleotide (AP1) directed specifically to platelet-type 12-LOX. It was found that AP1 strongly inhibited W256 cell growth by inducing apoptosis (Fig. 1) . The growth-inhibitory effect was observed at 0.1 ,uM and became apparent in a dose-dependent fashion, as determined by [3-(4,5- Fig. 1F ). By 24 h and 48 h, "40% and '80% of the cells were killed, respectively, by AP1 (Fig. 1A) . The growth inhibition induced by AP1 was the consequence of apoptosis induction, as revealed by phase contrast microscopy ( Fig. 1 B and C) , in situ apoptosis labeling using the TUNEL method and confocal microscopy ( Fig. 1 D and E) , and DNA fragmentation assay (Fig. 1F) . Electron fluorescence microscopy also corroborated apoptotic cell death (data not shown). The sense control oligonucleotide (SP1), a scrambled oligonucleotide with the same nucleotide composition as AP1, and an antisense oligonucleotide derived from the 3' untranslated region (3'-UTN) all failed to cause DNA fragmentation (Fig. 1F) leukocyte-type and the platelet-type) have been identified (11, 14, 15 (16) , demonstrated a dose-dependent inhibitory effect on W256 cell growth ( Fig. 2A) . The DNA fragmentation was observed with 10 ,uM BHPP treatment (12 h ) and the inhibitor revealed a dose-and time-dependent effect (Fig. 2B) . NDGA, a general LOX inhibitor, demonstrated the most potent apoptosis-inducing effect, inducing apoptosis at 0.1 ,uM 24 h after drug application. Two h after 2.5 ,uM NDGA treatment, numerous apoptotic cells with typical membrane blebbing could easily be seen (Fig. 2C) . At 4 h, the majority of cells in culture were dead and released membrane-bound apoptotic bodies (Fig. 2D) . DNA fragmentation assays revealed a similar time-and dose-dependent relationship (Fig. 2E) . NDGA-induced apoptosis declined at 210 AM. At 25 ,M, a mixed apoptosis and necrosis was observed, while at 250 ,uM, NDGA induced a rapid necrotic response that affected the whole cell population. Another general LOX inhibitor, 5,8,11-eicosatrienoic acid (ETI) (17) also induced potent cell death, with obvious effects observed at 5 ,uM (Fig. 2F) . Of the three selective 5-LOX inhibitors tested, caffeic acid (18) and 5,6-dehydro-arachidonic acid (19) did not induce apoptosis at the doses tested (5-100 ,uM and 1-50 ,M, respectively; Fig. 2 E and F) (Fig. 3B) . In fact, 12(S)-HPETE slightly enhanced the NDGA-induced apoptosis (Fig. 3B) . Interestingly, leukotriene B4 appeared to prevent NDGA-induced cell death (Fig. 3B) We next explored the potential biochemical mechanisms involved in the LOX-regulated apoptosis. Specifically, the role of three important molecules, i.e., bcl-2, bax, and p53, was examined in the apoptosis of W256 cells induced by LOX inhibitors and antisense oligonucleotides. Twenty-four hours after AP1 treatment, the 12-LOX protein was slightly downregulated (-3-fold; Fig. 4A) . By 48 h, 12-LOX protein decreased to nearly undetectable levels when normalized to corresponding actin protein levels (Fig. 4A) . This observation provided evidence that the antisense oligonucleotide was specifically blocking the 12-LOX gene expression. In contrast to the relatively slow downregulation in the 12-LOX protein, the bcl-2 protein level markedly decreased ('20-fold) and the level of bax, a protein known to complex with and antagonize the effect of bcl-2 (27), only marginally decreased (<2-fold) by 24 h. By 48 h, the bcl-2 protein dropped to an undetectable level. However, the bax protein level decreased by only "3-fold (Fig. 4A) . Similar blotting experiments with various LOX inhibitors (data not shown) revealed that NDGA, BHPP, baicalein, and CDC treatment all led to a more dramatic decrease in bcl-2 (5-20-fold) than in bax (1-3-fold). The effect of NDGA on bcl-2 and bax protein levels was also confirmed by flow cytometric analysis. The decrease of bcl-2 protein occurred temporally before the microscopic manifestation of W256 cell apoptosis. Fifteen minutes after NDGA treatment, bcl-2 protein level decreased by "3-fold; by 60 min it decreased further by >5-fold (Fig. 4B) . The inhibitor treatment, is a time-dependent decrease in the bcl-2/bax ratio, which is a critical determinant of apoptosis (27) , thus shifting the homeostasis toward a preference for apoptosis. It is unlikely that the different protein levels of bcl-2 and bax observed above were due to their differential tumover rates since bcl-2 is a long-lived protein with a half-life of 10-14 h (28, 29).
The above results prompted us to perform overexpression experiments. W256 cells were stably transfected with human bcl-2 cDNA under the control of cytomegalovirus early enhancer/promoter (pCMVbcl-2) or with the empty vector (pCMVneo) as a control. Three clones of transfectants that had been confirmed to express increased levels of bcl-2 and 2 control clones (Fig. 4C) were treated with NDGA or AP1 to induce apoptosis. As shown in Fig. 4E , all three bcl-2 overexpressers were significantly more resistant to apoptosis induction by either inducer. W256 cells appeared to express wild-type p53. Untreated W256 cells express barely detectable levels of p53 protein (Fig. 4D) . Treatment of W256 cells with the genotoxic drug Adriamycin induced a significant increase by 24 h (>5-fold) in the p53 protein (Fig. 4D) . The protein level of P2JWAF-1, a downstream target of the p53, did not undergo any significant alterations 24 h after Adriamycin treatment. However, by 48 h it was dramatically induced (>10-fold; Fig. 4D ). It is known that, in response to DNA damage, p53 protein induces P21WAF-. only when p53 is wild type (30) . Therefore, the above experimental findings suggest that p53 is wild type in W256 cells. This conclusion is further supported by the single strand conformation polymorphism analysis of exons 5-8 using primers derived from the rat p53 (31) (Fig. 2) . Third, W256 cells are known to express platelet-type 12-LOX (11, 13) that metabolizes AA almost exclusively to 12(S)-HETE (14, 15) . Previous experiments (12, 13) also documented that W256 cells biosynthesize both 12(S)-HETE and 15(S)-HETE, thus suggesting that W256 cells might express a 15-LOX activity. Fourth, supplementation of W256 cells with exogenous 12-or 15-HETE could partially block both oligonucleotide-and inhibitor-induced apoptosis. By contrast, the current studies suggest that 5-LOX may not be involved in regulating W256 cell survival, as evidenced by the inability of 5-LOX inhibitors to trigger apoptosis and of 5(S)-HETE to overcome NDGAinduced W256 cell death, although this LOX system has been implicated in regulating apoptosis of other tumor cells (32) .
The present study suggests that in W256 cells, the LOX system (i.e., 12-LOX and probably 15-LOX) is tightly or inherently coupled to cell survival and the cellular apoptotic machinery. This phenomenon is not unique to W256 cells; several cell lines such as human erythroleukemia (HEL) and rat MTLn-3 mammary adenocarcinoma cells also undergo apoptosis in response to treatment with oligonucleotides or LOX inhibitors (D.G.T. and K.V.H., unpublished results). The precise mechanism whereby the LOX pathway is coupled to apoptosis is unknown. However, the data presented points to a role of LOX pathway as a critical regulator of intracellular oxidation process in modulating cell survival. Intracellular oxidants (free radicals, oxidized intermediates of lipid and protein molecules, etc.) are closely involved in the apoptotic process. AA metabolism and mitochondrial electron transport are the two major sources for the generation of reactive oxidants. These reactive oxidation species not only directly damage important cellular components, but also regulate the expression of many other genes, including those implicated in cell death. Intriguingly, it was observed in this study that, after treatment of W256 cells with LOX antisense oligonucleotides or LOX inhibitors, there was a rapid decrease in the bcl-2 protein level. Based on the observations that W256 cell apoptosis induced by NDGA and other LOX inhibitors requires de novo protein synthesis and can be inhibited by peroxidation inhibitors (D.G.T. and K.V.H., unpublished results), it is tempting to hypothesize that the LOX system may directly or indirectly (e.g., via reactive free radicals) regulate certain cell death genes (e.g., Interleukin I Converting Enzyme-related proteases), which in turn regulate the bcl-2 protein. Future studies will be directed to dissecting the role and molecular mechanisms of individual LOXs in regulating cell survival and apoptosis, identifying the genes regulated by the LOX system, and elucidating the cause-and-effect relationship between the LOX, intracellular redox homeostasis, and important apoptosis-regulatory molecules such as bcl-2, bax, and proteases. 
